Foghorn Therapeutics to Present in Two Upcoming Investor Conferences

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will present at two upcoming investor conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 10:00 am ET, featuring a presentation and one-on-one meetings. The Goldman Sachs 42nd Annual Healthcare Conference will take place on June 8, 2021, at 8:00 am ET, including a fireside chat and one-on-one meetings. Interested investors can access the live webcasts through the company’s website under the “Events & Presentations” section.

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.

Events:

Jefferies Virtual Healthcare Conference
Format: Presentation and 1x1s
Tuesday, June 1, 2021
10:00am ET

Goldman Sachs 42^nd Annual Healthcare Conference
Format: Fireside Chat and 1x1s
Tuesday, June 8, 2021
8:00am ET

A live webcast of both presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics
fcavalie@foghorntx.com

Gregory Kelley, Ogilvy
gregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics
areine@foghorntx.com

Hans Vitzthum, LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

FAQ

When will Foghorn Therapeutics be presenting at the Jefferies Virtual Healthcare Conference?

Foghorn Therapeutics will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 am ET.

What is the format of the Goldman Sachs 42nd Annual Healthcare Conference for FHTX?

FHTX will participate in a fireside chat and one-on-one meetings at the Goldman Sachs 42nd Annual Healthcare Conference on June 8, 2021, at 8:00 am ET.

Where can I watch the FHTX presentations live?

Live webcasts of FHTX presentations can be accessed on the company's website under the 'Events & Presentations' section.

What type of medicines does Foghorn Therapeutics develop?

Foghorn Therapeutics develops a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.

What is the primary focus of FHTX's research?

FHTX primarily focuses on oncology, developing multiple product candidates through its Gene Traffic Control platform.